Upsher-Smith Laboratories LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$6.8M
Doctors Paid
9,248
Transactions
41,752
2024 Total
$136,668
Payment Breakdown by Category
Research$5.2M (77.3%)
Food & Beverage$735,396 (10.9%)
Consulting$370,021 (5.5%)
Travel$70,433 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.2M | 485 | 77.3% |
| Food and Beverage | $735,396 | 40,775 | 10.9% |
| Consulting Fee | $370,021 | 145 | 5.5% |
| Honoraria | $209,466 | 88 | 3.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $140,079 | 74 | 2.1% |
| Travel and Lodging | $70,433 | 180 | 1.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $5,900 | 3 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $1,277 | 1 | 0.0% |
| Education | $63.00 | 1 | 0.0% |
Payments by Type
Research
$5.2M
485 transactions
General
$1.5M
41,267 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| VOGELXO(R) ABPM STUDY IN HYPOGANDAL MEN | $3.2M | 0 | 223 |
| A PHASE 4, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTS OF VOGELXO(R) ON 24-HOUR AMBULATORY BLOOD PRESSURE MONITORING IN HYPOGONADAL MEN USING THERAPEUTIC TESTOSTERONE REPLACEMENT THERAPY | $497,015 | 0 | 23 |
| A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intranasal Midazolam USL261 in the Outpatient Treatment of Subjects with Seizure Clusters | $420,093 | 0 | 60 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE | $375,621 | 2 | 126 |
| An Open-label Extension Safety and Efficacy Study of Intranasal Midazolam in the Outpatient Treatment of Subjects with Seizure Clusters | $152,258 | 0 | 20 |
| A Phase 12 Dose-escalation of USL311 as Single Agent and in Combination with Lomustine CCNU in Subjects with Advanced Solid Tumors, with Subsequent Single Agent and Combination Phase 2 Cohorts for Subjects with RelapsedRecurrent Glioblastoma Multiforme GBM | $132,999 | 0 | 2 |
| A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray USL261 for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit EMU | $131,530 | 0 | 19 |
| Interfacing a Mobile Health Delivery Module for Rural Patients with Refractory Epilepsy | $101,190 | 0 | 3 |
| Defining the risk factors, prevelance, and consequences of pediatric seizure clusters a prospective, observational study at two tertiary epilepsy centers | $81,017 | 0 | 2 |
| P361-502 | $51,598 | 0 | 2 |
| Analysis of Healthcare Utilization and Comfort of Use for Patients Receiving Intravenous Formulation of Midazolam that is Being Administered Intranasally Verses Rectal Diazepam for Abortive Seizures | $20,255 | 0 | 1 |
| Retrospective Analysis of Healthcare Utilization and Comfort of Use for Patients Receiving Intravenous Formulation of Midazolam that is Being Administered Intranasally Verses Rectal Diazepam for Abortive Seizures | $14,857 | 0 | 2 |
| Carotid plaque composition by MRI during lipid thereapy CPC | $6,410 | 0 | 1 |
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL-GROUP PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE | $1,425 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Marshall Freeman, Md, MD | Specialist | Greensboro, NC | $233,952 | $0 |
| Peter Mcallister, M.d, M.D | Neurology | Fairfield, CT | $52,922 | $0 |
| Dr. Jack Schim, M.d, M.D | Neurology | Carlsbad, CA | $43,636 | $0 |
| Christina Treppendahl, Fnp-Bc, FNP-BC | Nurse Practitioner | Ridgeland, MS | $39,937 | $0 |
| Susan Hutchinson, Md, MD | Adult Medicine | Laguna Hills, CA | $25,586 | $0 |
| Dr. Philip Chaikin, M.d, M.D | Clinical Pharmacology | Belle Mead, NJ | $20,000 | $0 |
| Dr. Shaun Hussain, Md, Ms, MD, MS | Neurology | Los Angeles, CA | $17,522 | $0 |
| Steve Chung, M.d, M.D | Neurology | Phoenix, AZ | $15,590 | $0 |
| Frank Berenson, Md, MD | Neurology | Atlanta, GA | $15,043 | $0 |
| Stacey Steeves, Md, MD | Neurology | Salt Lake City, UT | $12,035 | $0 |
| Dr. Merle Diamond, Md, MD | Internal Medicine | Chicago, IL | $11,811 | $0 |
| Dr. Gilbert Block, Md, MD | Neurology | Haverford, PA | $9,689 | $0 |
| Dr. James Wheless, Md, MD | Neurology with Special Qualifications in Child Neurology | Memphis, TN | $8,963 | $0 |
| Robert Cowan, Md, MD | Neurology | Stanford, CA | $8,928 | $0 |
| Dr. Brian Loftus, M.d, M.D | Neurology | Bellaire, TX | $7,832 | $0 |
| P. Christopher Gottschalk, M.d, M.D | Neurology | Fairfield, CT | $7,609 | $0 |
| Dr. Alan Rapoport, M.d, M.D | Neurology | Los Angeles, CA | $7,560 | $0 |
| Dr. Judy Lane, Md, MD | Specialist | Englewood, CO | $6,763 | $0 |
| Dr. Shivang Joshi, Md, MD | Neurology | Westborough, MA | $6,710 | $0 |
| Andrew Hershey, M.d, M.D | Neurology with Special Qualifications in Child Neurology | Cincinnati, OH | $6,339 | $0 |
| Kenneth Mack, M.d, M.D | Neurology | Madison, WI | $6,247 | $0 |
| Dr. Christopher O'carroll, M.d, M.D | Neurology | Newport Beach, CA | $5,616 | $0 |
| Dr. Elizabeth Thiele, Md Phd, MD PHD | Neurology with Special Qualifications in Child Neurology | Boston, MA | $5,342 | $0 |
| Dr. Brian Droker, Md, MD | Neurology | Carlsbad, CA | $5,292 | $0 |
| Elaine Wirrell, Md, MD | Neurology | Rochester, MN | $5,180 | $0 |
Ad
Top Products
- ZEMBRACE SYMTOUCH $3.2M
- QUDEXY XR Topiramate Extended Release Capsules $532,921
Associated Products (16)
- ZEMBRACE SYMTOUCH $3.4M
- QUDEXY XR Topiramate Extended Release Capsules $532,921
- TOSYMRA $391,365
- TOPIRAMATE $364,028
- VOGELXO $339,052
- VOGELXO TESTOSTERONE GEL CIII $211,488
- Vogelxo $183,205
- TOSYMRA SUMATRIPTAN NASAL SPRAY $159,420
- VIGADRONE (vigabatrin) for Oral Solution $97,849
- ZEMBRACE SYMTOUCH SUMATRIPTAN INJECTION $53,739
- Zembrace SymTouch Sumatriptan Injection $16,189
- TORPENZ $12,723
- QUDEXY $12,345
- Tosymra Sumatriptan Nasal Spray $11,380
- QUDEXY XR TOPIRAMATE EXTENDED RELEASE CAPSULES $10,958
- VIGADRONE $10,833
Payment Categories
- Food & Beverage $735,396
- Consulting $370,021
- Travel & Lodging $70,433
- Research $5.2M
About Upsher-Smith Laboratories LLC
Upsher-Smith Laboratories LLC has made $6.8M in payments to 9,248 healthcare providers, recorded across 41,752 transactions in the CMS Open Payments database. In 2024, the company paid $136,668. The top product by payment volume is ZEMBRACE SYMTOUCH ($3.2M).
Payments were distributed across 148 medical specialties. The top specialty by payment amount is Neurology ($643,694 to 2,572 doctors).
Payment categories include: Food & Beverage ($735,396), Consulting ($370,021), Research ($5.2M), Travel & Lodging ($70,433).
Upsher-Smith Laboratories LLC is associated with 16 products in the CMS Open Payments database, including ZEMBRACE SYMTOUCH, QUDEXY XR Topiramate Extended Release Capsules, and TOSYMRA.